 |
|
Maximum: 0 CME cr.
0 new discussion posts (4 published)
Sign in to view your progression
|
|
ON-DEMAND
Introduction
|
|
|
ON-DEMAND
P53 mutations, Precursor lesions mutations and immunological markers- what do they signify?
|
|
|
ON-DEMAND
BRCA mutations – Pathological and Variants of unknown significance and other genes associated with hereditary ovarian cancer
|
|
|
ON-DEMAND
CA125 and serological markers of ovarian cancer- Anything new in last decade?
|
|
|
ON-DEMAND
Angiogenic pathways- significance in ovarian cancer and role of targeted anti-angiogenic therapy
|
|
|
ON-DEMAND
Homologous Recombination Repair - How should HRD be determined and is it clinically useful? (incl. ovarian and endometrial cancers)
|
|
|
ON-DEMAND
Targeting HR Deficiency- when and with which agents?
|
|
|
ON-DEMAND
Q&A
|
|
{{ help_message }}
{{filter}}